Improvement of the bitter taste of drugs by complexation with cyclodextrins: Applications, evaluations and mechanisms

Therapeutic Delivery

Volumn 3, Issue 5, 2012, Pages 633-644

  Arima, Hidetoshi ^a   Higashi, Taishi ^a   Motoyama, Keiichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOFENAC; ALPHA CYCLODEXTRIN; ARTEMETHER; ARUNDIC ACID; BENCYCLANE FUMARATE; BETA CYCLODEXTRIN; CETIRIZINE; CHLORPHENIRAMINE; CLOFIBRATE; CYCLODEXTRIN; DIPHENHYDRAMINE; EPINASTINE; EXCIPIENT; FAMOTIDINE; FEMOXETINE; FLURBIPROFEN; GAMMA CYCLODEXTRIN; HYDROXYZINE; IBUPROFEN; LEVOCETIRIZINE; MECLOFENOXATE; OSELTAMIVIR; PIRPROFEN; RIZATRIPTAN; SULOCTIDIL; TETRACHLOROETHYLENE; TIARAMIDE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; ZIPEPROL;

AQUEOUS SOLUTION; BITTER TASTE; CHEMICAL ANALYSIS; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CIRCULAR DICHROISM; COMPLEX FORMATION; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG COATING; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; HEMOLYSIS; HYDROPHOBICITY; MASKING; MECHANICAL PROBE; MOLECULAR INTERACTION; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON MOTIVE FORCE; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; REVIEW; SOLID STATE; STOICHIOMETRY; TASTE MASKING;

EID: 84861302958     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.28     Document Type: Review

References (84)

1. Chandrashekar J, Hoon MA, Ryba NJ, Zuker CS. The receptors and cells for mammalian taste. Nature 444(7117), 288-294 (2006).
2. Chen X, Gabitto M, Peng Y, Ryba NJ, Zuker CS. A gustotopic map of taste qualities in the mammalian brain. Science 333(6047), 1262-1266 (2011).
3. Adler E, Hoon MA, Mueller KL, Chandrashekar J, Ryba NJ, Zuker CS. A novel family of mammalian taste receptors. Cell 100(6), 693-702 (2000).
4. Chandrashekar J, Mueller KL, Hoon MA et al. T2Rs function as bitter taste receptors. Cell 100(6), 703-711 (2000).
5. Huang AL, Chen X, Hoon MA et al. The cells and logic for mammalian sour taste detection. Nature 442(7105), 934-938 (2006).
6. Ishimaru Y, Inada H, Kubota M, Zhuang H, Tominaga M, Matsunami H. Transient receptor potential family members PKD1L3 and PKD2L1 form a candidate sour taste receptor. Proc. Natl Acad. Sci. USA 103(33), 12569-12574 (2006).
7. Li X, Staszewski L, Xu H, Durick K, Zoller M, Adler E. Human receptors for sweet and umami taste. Proc. Natl Acad. Sci USA 99(7), 4692-4696 (2002).
8. Matsunami H, Montmayeur JP, Buck LB. A family of candidate taste receptors in human and mouse. Nature 404(6778), 601-604 (2000).
9. Mueller KL, Hoon MA, Erlenbach I, Chandrashekar J, Zuker CS, Ryba NJ. The receptors and coding logic for bitter taste. Nature 434(7030), 225-229 (2005).
10. Nelson G, Chandrashekar J, Hoon MA et al. An amino-acid taste receptor. Nature 416(6877), 199-202 (2002).
11. Nelson G, Hoon MA, Chandrashekar J, Zhang Y, Ryba NJ, Zuker CS. Mammalian sweet taste receptors. Cell 106(3), 381-390 (2001).
12. Zhao GQ, Zhang Y, Hoon MA et al. The receptors for mammalian sweet and umami taste. Cell 115(3), 255-266 (2003).
13. Nunn T, Williams J. Formulation of medicines for children. Br. J. Clin. Pharmacol. 59(6), 674-676 (2005).
14. Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev. Ind. Pharm. 30(5), 429-448 (2004).
15. Shammari SA, Khoja T, Yamani MJ. Compliance with short-term antibiotic therapy among patients attending primary health centres in Riyadh, Saudi Arabia. J. R. Soc. Health 115(4), 231-234 (1995).
16. Dhoka MV, Nimbalkar UA, Pande A. Preparation of cefpodoxime proxetil-polymeric microspheres by the emulsion solvent diffusion method for taste masking. Int. J. Chem. Tech. Res. 3(1), 411-419 (2011).
17. Ayenew Z, Puri V, Kumar L, Bansal AK. Trends in pharmaceutical taste masking technologies: a patent review. Recent Pat. Drug Deliv. Formul. 3(1), 26-39 (2009).
18. Behzadi SS, Toegel S, Viernstein H. Innovations in coating technology. Recent Pat. Drug Deliv. Formul. 2(3), 209-230 (2008).
19. Douroumis D. Practical approaches of taste masking technologies in oral solid forms. Expert Opin. Drug Deliv. 4(4), 417-426 (2007).
20. Douroumis D. Orally disintegrating dosage forms and taste-masking technologies; 2010. Expert Opin. Drug Deliv. 8(5), 665-675 (2011).
21. Gryczke A, Schminke S, Maniruzzaman M, Beck J, Douroumis D. Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion. Colloids Surf. B Biointerfaces 86(2), 275-284 (2011).
22. Hamashita T, Matsuzaki M, Ono T et al. Granulation of core particles suitable for film coating by agitation fluidized bed II. A proposal of a rapid dissolution test for evaluation of bitter taste of ibuprofen. Chem. Pharm. Bull. (Tokyo) 56(7), 883-887 (2008).
23. Hamashita T, Nakagawa Y, Aketo T, Watano S. Granulation of core particles suitable for film coating by agitation fluidized bed I. Optimum formulation for core particles and development of a novel friability test method. Chem. Pharm. Bull. (Tokyo) 55(8), 1169-1174 (2007).
24. Yoshida T, Tasaki H, Maeda A, Katsuma M, Sako K, Uchida T. Optimization of salting-out taste-masking system for micro-beads containing drugs with high solubility. Chem. Pharm. Bull. (Tokyo) 56(11), 1579-1584 (2008).
25. Yoshida T, Tasaki H, Maeda A, Katsuma M, Sako K, Uchida T. Salting-out taste-masking system generates lag time with subsequent immediate release. Int. J. Pharm. 365(1-2), 81-88 (2009).
26. Yoshida T, Tasaki H, Maeda A, Katsuma M, Sako K, Uchida T. Mechanism of controlled drug release from a salting-out taste-masking system. J. Control. Release 131(1), 47-53 (2008).
27. Sikandar MK, Makviya R, Sharma PK. Taste masking: an important pharmaceutical technology for the improvement of organoleptic property of pharmaceutical active agents. Eur. J. Biol. Sci. 3(3), 67-71 (2011).
28. Albers E, Muller BW. Cyclodextrin derivatives in pharmaceutics. Crit. Rev. Ther. Drug Carrier Syst. 12(4), 311-337 (1995).
29. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59(7), 645-666 (2007).
30. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 6(2), E329-E357 (2005).
31. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 3(12), 1023-1035 (2004).
32. Li J, Loh XJ. Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. Adv. Drug Deliv. Rev. 60(9), 1000-1017 (2008).
33. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J. Pharm. Pharmacol. 62(11), 1607-1621 (2010).
34. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 98(5), 2045-2076 (1998).
35. Uekama K, Otagiri M. Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carrier Syst. 3(1), 1-40 (1987).
36. Debouzy JC, Fauvelle F, Crouzy S et al. Mechanism of a-cyclodextrin induced hemolysis. A study of the factors controlling the association with serine-, ethanolamine-, and choline-phospholipids. J. Pharm. Sci. 87(1), 59-66 (1998).
37. Fauvelle F, Debouzy JC, Crouzy S, Goschl M, Chapron Y. Mechanism of a-cyclodextrin-induced hemolysis. The two-step extraction of phosphatidylinositol from the membrane. J. Pharm. Sci. 86(8), 935-943 (1997).
38. Irie T, Otagiri M, Sunada M et al. Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro. J. Pharmacobiodyn. 5(9), 741-744 (1982).
39. Ohtani Y, Irie T, Uekama K, Fukunaga K, Pitha J. Differential effects of a-, b- and g-cyclodextrins on human erythrocytes. Eur. J. Biochem. 186(1-2), 17-22 (1989
40. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86(2), 147-162 (1997).
41. Loftsson T, Jarho P, Masson M, Jarvinen T. Cyclodextrins in drug delivery. Expert Opin. Drug Deliv. 2(2), 335-351 (2005).
42. Uekama K, Imai T, Maeda T, Irie T, Hirayama F, Otagiri M. Improvement of dissolution and suppository release characteristics of flurbiprofen by inclusion complexation with heptakis(2,6-di-O-methyl)-b-cyclodextrin. J. Pharm. Sci. 74(8), 841-845 (1985).
43. Sharma S, Lewis S. Taste masking technologies: a review. Int. J. Pharm. Sci. 2(2), 6-13 (2010).
44. Kumazawa T, Nomura T, Kurihara K. Liposomes as model for taste cells: receptor sites for bitter substances including N-C=S substances and mechanism of membrane potential changes. Biochemistry 27(4), 1239-1244 (1988).
45. Okahata Y, En-Na G, Ebato H. Synthetic chemoreceptive membranes. Sensing bitter or odorous substances on a synthetic lipid multibilayer film by using quartz-crystal microbalances and electric responses. Anal. Chem. 62(14), 1431-1438 (1990).
46. Ono N, Miyamoto Y, Ishiguro T et al. Reduction of bitterness of antihistaminic drugs by complexation with b-cyclodextrins. J. Pharm. Sci. 100(5), 1935-1943 (2011).
47. Funasaki N, Uratsuji I, Okuno T, Hirota S, Neya S. Masking mechanisms of bitter taste of drugs studied with ion selective electrodes. Chem. Pharm. Bull. (Tokyo) 54(8), 1155-1161 (2006).
48. Funasaki N, Kawaguchi R, Ishikawa S, Hada S, Neya S, Katsu T. Quantitative estimation of the bitter taste intensity of oxyphenonium bromide reduced by cyclodextrins from electromotive force measurements. Anal. Chem. 71(9), 1733-1736 (1999).
49. Kataoka M, Miyanaga Y, Tsuji E, Uchida T. Evaluation of bottled nutritive drinks using a taste sensor. Int. J. Pharm. 279(1-2), 107-114 (2004).
50. Miyanaga Y, Inoue N, Ohnishi A, Fujisawa E, Yamaguchi M, Uchida T. Quantitative prediction of the bitterness suppression of elemental diets by various flavors using a taste sensor. Pharm. Res. 20(12), 1932-1938 (2003).
51. Takagi S, Toko K, Wada K, Yamada H, Toyoshima K. Detection of suppression of bitterness by sweet substance using a multichannel taste sensor. J. Pharm. Sci. 87(5), 552-555 (1998).
52. Toko K. Electronic tongue. Biosens. Bioelectron. 13(6), 701-709 (1998).
53. Uchida T, Kobayashi Y, Miyanaga Y et al. A new method for evaluating the bitterness of medicines by semi-continuous measurement of adsorption using a taste sensor. Chem. Pharm. Bull. (Tokyo) 49(10), 1336-1339 (2001).
54. Uchida T, Tanigake A, Miyanaga Y et al. Evaluation of the bitterness of antibiotics using a taste sensor. J. Pharm. Pharmacol. 55(11), 1479-1485 (2003).
55. Mady FM, Abou-Taleb AE, Khaled KA et al. Enhancement of the aqueous solubility and masking the bitter taste of famotidine using drug/SBE-b-CyD/ povidone K30 complexation approach. J. Pharm. Sci. 99(10), 4285-4294 (2010).
56. Mady FM, Abou-Taleb AE, Khaled KA et al. Evaluation of carboxymethyl-b-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine. Int. J. Pharm. 397(1-2), 1-8 (2010).
57. Szejtli J, Szente L. Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur. J. Pharm. Biopharm. 61(3), 115-125 (2005).
58. Woertz K, Tissen C, Kleinebudde P, Breitkreutz J. Rational development of taste masked oral liquids guided by an electronic tongue. Int. J. Pharm. 400(1-2), 114-123 (2010).
59. Miyamoto Y, Nakahara M, Motoyama K et al. Improvement of some physicochemical properties of arundic acid, (R)-(-)-2- propyloctanonic acid, by complexation with hydrophilic cyclodextrins. Int. J. Pharm. 413(1-2), 63-72 (2011).
60. Toda J, Misaki M, Konno A, Wada T, Yasumatsu K. Interaction of cyclodextrins with taste substances. Proc. 4th Int. Flavour Conference 1, 19-34 (1985).
61. Shah PP, Mashru RC. Formulation and evaluation of taste masked oral reconstitutable suspension of primaquine phosphate. AAPS PharmSciTech 9(3), 1025-1030 (2008).
62. Cabral FP, Bergamo BB, Dantas CA, Riul A, Jr, Giacometti JA. Impedance E-tongue instrument for rapid liquid assessment. Rev. Sci. Instrum. 80(2), 026107 (2009).
63. Gupta H, Sharma A, Kumar S, Roy SK. E-tongue: a tool for taste evaluation. Recent Pat. Drug Deliv. Formul. 4(1), 82-89 (2010).
64. Rachid O, Simons FE, Rawas-Qalaji M, Simons KJ. An electronic tongue: evaluation of the masking efficacy of sweetening and/or flavoring agents on the bitter taste of epinephrine. AAPS PharmSciTech 11(2), 550-557 (2010).
65. Stojanov M, Wimmer R, Larsen KL. Study of the inclusion complexes formed between cetirizine and a-, b-, and g-cyclodextrin and evaluation on their taste-masking properties. J. Pharm. Sci. 100(8), 3177-3185 (2011).
66. Shah PP, Mashru RC. Palatable reconstitutable dry suspension of artemether for flexible pediatric dosing using cyclodextrin inclusion complexation. Pharm. Dev. Technol. 15(3), 276-285 (2010).
67. Birhade ST, Bankar VH, Gaikwad, PD, Pawar SP. Preparation and evaluation of cyclodextrin based binary systems for taste masking. J. Pharm. Sci. Drug Res. 2(3), 199-203 (2010).
68. Sevukarajan M, Thanuja B, Rahul N. Novel inclusion complexes of oseltamivir phosphate-with b-cyclodextrin: physico-chemical characterization. J. Pharm. Sci. Res. 2(9), 583-589 (2010).
69. Mahesh A, Shastri N, Sadanandam M. Development of taste masked fast disintegrating films of levocetirizine dihydrochloride for oral use. Curr. Drug Deliv. 7(1), 21-27 (2010).
70. Patel AR, Vavia PR. Preparation and evaluation of taste masked famotidine formulation using drug/b-cyclodextrin/ polymer ternary complexation approach. AAPS PharmSciTech 9(2), 544-550 (2008).
71. Uekama K, Arima H, Irie T, Matsubara K, Kuriki T. Sustained release of buserelin acetate, a luteinizing hormone-releasing hormone agonist, from an injectable oily preparation utilizing ethylated b-cyclodextrin. J. Pharm. Pharmacol. 41(12), 874-876 (1989).
72. Matsubara K, Irie T, Uekama K. Spectroscopic characterization of the inclusion complex of a luteinizing hormone-releasing hormone agonist, buserelin acetate, with dimethyl-b-cyclodextrin. Chem. Pharm. Bull. (Tokyo) 45(2), 378-383 (1997).
73. Tokihiro K, Irie T, Uekama K. Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous solution. Chem. Pharm. Bull. (Tokyo) 45(3), 525-531 (1997).
74. Tavornvipas S, Tajiri S, Hirayama F, Arima H, Uekama K. Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone. Pharm. Res. 21(12), 2369-2376 (2004).
75. Tavornvipas S, Hirayama F, Takeda S, Arima H, Uekama K. Effects of cyclodextrins on chemically and thermally induced unfolding and aggregation of lysozyme and basic fibroblast growth factor. J. Pharm. Sci. 95(12), 2722-2729 (2006).
76. Abe K, Irie T, Uekama K. Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropyl-b-cyclodextrin. Chem. Pharm. Bull. (Tokyo) 43(12), 2232-2237 (1995).
77. Matsubara K, Ando Y, Irie T, Uekama K. Protection afforded by maltosyl-b-cyclodextrin against a-chymotrypsin-catalyzed hydrolysis of a luteinizing hormone-releasing hormone agonist, buserelin acetate. Pharm. Res. 14(10), 1401-1405 (1997).
78. Irie T, Uekama K. Cyclodextrins in peptide and protein delivery. Adv. Drug Deliv. Rev. 36(1), 101-123 (1999).
79. Arima H, Yunomae K, Hirayama F, Uekama K. Contribution of P-glycoprotein to the enhancing effects of dimethyl-b-cyclodextrin on oral bioavailability of tacrolimus. J. Pharmacol. Exp. Ther. 297(2), 547-555 (2001).
80. Arima H, Yunomae K, Morikawa T, Hirayama F, Uekama K. Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-b-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. Pharm. Res. 21(4), 625-634 (2004).
81. Yunomae K, Arima H, Hirayama F, Uekama K. Involvement of cholesterol in the inhibitory effect of dimethyl-b-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett. 536(1-3), 225-231 (2003).
82. Motoyama K, Toyodome H, Onodera R et al. Involvement of lipid rafts of rabbit red blood cells in morphological changes induced by methylated b-cyclodextrins. Biol. Pharm. Bull. 32(4), 700-705 (2009).
83. Ohkubo S, Nakahata N. Role of lipid rafts in trimeric G protein-mediated signal transduction. Yakugaku Zasshi 127(1), 27-40 (2007).
84. Katsuragi Y, Kurihara K. Specific inhibitor for bitter taste. Nature 365(6443), 213-214 (1993)